Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 29, Issue 8, 2014, Pages 1554-1562

  Moradi, Hamid ^a   Streja, Elani ^a   Kashyap, Moti L ^a,b   Vaziri, Nosratola D ^a   Fonarow, Gregg C ^c   Kalantar Zadeh, Kamyar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiovascular disease; end stage renal disease; hemodialysis; high density lipoprotein; mortality

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; REFERENCE VALUE; UNITED STATES;

CARDIOVASCULAR DISEASE; END-STAGE RENAL DISEASE; HEMODIALYSIS; HIGH-DENSITY LIPOPROTEIN; MORTALITY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84905019304     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu022     Document Type: Article

References (55)

1. United States Renal Data System. USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. USRDS Annual Report. National Institutes of Health NIoDaDaKD, Bethesda, MD: NIH/NIDDK, 2008. http://www.usrds.org/atlas-2006.htm (6 August, 2010, date last accessed)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. Kovesdy CP, Trivedi BK, Anderson JE. Associations of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort study. Adv Chronic Kidney Dis 2006; 13: 183-188
4. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538
5. Noori N, Caulfield MP, Salameh WA et al. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2861-2870
6. Aminzadeh MA, Nicholas SB, Norris KC et al. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 2013; 28: 2038-2045
7. Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of proteinenergy wasting in non-dialysis-dependent chronic kidney disease: Reconciling low protein intake with nutritional therapy. Am J Clin Nutr 2013; 97: 1163-1177
8. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease Nephrol Dial Transplant 2004; Suppl 5: V67-V72
9. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013; 38: 136-148
10. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: Potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22: 545-551
11. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des 2005; 11: 3061-3072
12. Obryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006; 37: 208-222
13. Botham KM, Moore EH, De Pascale C et al. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007; 35: 454-458
14. Gleissner CA, Leitinger N, Ley K. Effects of native and modified lowdensity lipoproteins on monocyte recruitment in atherosclerosis. Hypertension 2007; 50: 276-283
15. Davidson MH, Toth PP. High-density lipoprotein metabolism: Potential therapeutic targets. Am J Cardio 2007; 100: N32-n40
16. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: From bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23: 1724-1731
17. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046
18. Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891
19. Ansell BJ, Navab M, Hama S et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756
20. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: Beyond reverse cholesterol transport. Curr Drug Targets 2008; 9: 196-203
21. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256: 2835-2838
22. Sharrett AR, Ballantyne CM, Coady SA et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-1113
23. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310
24. Gordon DJ, Rifkind BM. High-density lipoprotein-The clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316
25. Moradi H, Pahl MV, Elahimehr R et al. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85
26. Pahl MV, Ni Z, Sepassi L et al. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant 2009; 24: 2541-2546
27. Moradi H, Said HM, Vaziri ND. Post-Transcriptional nature of uremiainduced downregulation of hepatic apolipoprotein A-I production. Transl Res 2013; 161: 477-485
28. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-1466
29. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 2006; 10: 1-7
30. Kalantar-Zadeh K, Kopple JD, Kamranpour N et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007; 72: 1149-1156
31. Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303
32. Honda H, Ueda M, Kojima S et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012; 220: 493-501
33. Hatamizadeh P, Ravel V, Lukowsky LR et al. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 2889-2898
34. Lertdumrongluk P, Lau WL, Park J et al. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 2013; 28: 2535-2545
35. Centers for Disease Control and Prevention NHANES 2009-2010: Laboratory files, "HDL-Cholesterol'. http://www.cdc.gov/nchs/nhanes/nhanes2009-2010/ lab09-10.htm (January, 2013, date last accessed)
36. Kinosian B, Glick H, Garland G. Cholesterol and coronary artery disease: Predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641-647
37. Ray K, Wainwright NW, Visser L et al. Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 2012; 98: 780-785
38. Moradi H, Ganji S, Kamanna V et al. Increased monocyte adhesionpromoting capacity of plasma in end-stage renal disease-response to antioxidant therapy. Clin Nephrol 2010; 74: 273-281
39. Navab M, Reddy ST, Van Lenten BJ et al. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50: S145-S149
40. Zheng C, Aikawa M. High-Density Lipoproteins: From Function to Therapy. J Am Coll Cardiol 2012; 60: 2380-2383
41. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-135
42. Yamamoto S, Yancey PG, Ikizler TA et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012; 60: 2372-2379
43. Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947
44. Moradi H, Vaziri ND, Kashyap ML et al. Role of HDL dysfunction in endstage renal disease: A double-edged sword. J Ren Nutr 2013; 23: 203-206
45. Huang CY, Lin FY, Shih CM et al. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating rho-Associated kinase pathways. Arterioscler Thromb Vasc Biol 2012; 32: 2405-2417
46. Nagano M, Yamashita S, Hirano K et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004; 11: 110-121
47. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97: 2917-2923
48. Agerholm-Larsen B, Nordestgaard BG, Steffensen R et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101: 1907-1912
49. Kimura H, Miyazaki R, Suzuki S et al. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis 2001; 38: 70-76
50. Duffy D, Holmes DN, Roe MT et al. The impact of high-density lipoprotein cholesterol levels on long-Term outcomes after non-ST-elevation myocardial infarction. Am Heart J 2012; 163: 705-713
51. Corsetti JP, Zareba W, Moss AJ et al. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006; 187: 191-197
52. Corsetti JP, Salzman P, Ryan D et al. Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels. PLoS ONE 2013; 8: E68920
53. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
54. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
55. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407